NIRS for AKI in Preterm Infants (nNIRS-AKI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03384173|
Recruitment Status : Recruiting
First Posted : December 27, 2017
Last Update Posted : January 24, 2019
|Condition or disease||Intervention/treatment||Phase|
|Acute Kidney Injury Premature Infant||Device: Near Infrared Spectroscopy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Use of NIRS to Detect Acute Kidney Injury in Preterm Infants|
|Actual Study Start Date :||April 25, 2018|
|Estimated Primary Completion Date :||September 1, 2019|
|Estimated Study Completion Date :||September 1, 2019|
Experimental: NIRS monitoring
These infants will be monitored with NIRS
Device: Near Infrared Spectroscopy
Application of regional NIRS sensors to brain and kidney sites in the first 48 hours after birth to monitor regional tissue oxygenation for the first 7 days of age.
Other Name: NIRS
- Renal NIRS tissue oxygenation differential [ Time Frame: Days 1-7 of age ]Comparison of Renal saturation (Rsat) in patients with AKI to those without AKI.
- Correlation of renal NIRS values to serum creatinine and urine output [ Time Frame: Days 1-7 of age ]In patients with AKI, renal NIRS values (Rsat) will be correlated with changes in serum creatinine and urine output.
- Effect of neonatal medications on renal NIRS values [ Time Frame: Days 1-7 of age ]Renal saturation values following administration of neonatal medications will be compared to mean renal saturation values for each specific patient.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03384173
|Contact: Matthew Harer, MDfirstname.lastname@example.org|
|Contact: Ryan McAdams, MD||608-417-6236|
|United States, Wisconsin|
|UnityPoint Health Meriter Hospital||Recruiting|
|Madison, Wisconsin, United States, 53715-1507|
|Contact: Matthew Harer, MD email@example.com|